Motif Bio PLC

Motif Bio receives vote of confidence as it raises £2.7mln

Chief executive Graham Lumsden said: "We are encouraged by the support shown by both new and existing investors as we strengthen our balance sheet"

Motif has developed an antibiotic to tackle acute skin infections

Motif Bio PLC (LON:MTFB, NASDAQ:MTFB) received a monetary boost – and by extension a vote of confidence in its prospects – as it raised £2.7mln via a share placing.

The cash will fund the business through the coming months as it meets with officials at the US Food & Drug Administration (FDA) to discuss the future of its antibiotic, iclaprim.

The treatment, which was developed to tackle acute bacterial skin infections, was knocked by the FDA last month.

The watchdog wants additional data so it can “further evaluate the risk for liver toxicity” before it decides whether or not to grant new drug approval. As one of Motif’s advisers pointed out, this wasn’t a straight ‘no’. So there may still be some hope.

Of course, Motif is keen “to discuss potential options to address the deficiencies” with the information it had furnished. But ahead of the fundraiser, there had been real concerns the business might run out of cash.

Meeting scheduled

A meeting with the FDA is scheduled for May 3, and the company expects a response a month later.

Proceeds from the placing, which was completed at 6p a share, will provide a financial runway long enough to see it past the date it receives the minutes from the regulator in June.

Chief executive Graham Lumsden said: "We are encouraged by the support shown by both new and existing investors as we strengthen our balance sheet.

“The company now expects to be funded through completion of the FDA meeting and receipt of the minutes, which should provide guidance regarding the path forward for iclaprim."

Quick facts: Motif Bio PLC

Price: £0.03

Market: AIM
Market Cap: £9.08 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...



Investor Update: AfriTin Mining produces first concentrate from Uis mine

Headlines from the Proactive UK newsroom. AfriTin Mining (LON:ATM) has produced is first tin concentrate from the Uis mine in Namibia. The miner has also signed an offtake deal with a Thai group.  BlueRock Diamonds (LON:BRD) has sold a fifth diamond this year for more than US$50,000....

6 days, 7 hours ago

2 min read